quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·3d
PRRelease
Amneal Pharmaceuticals Inc. logo

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily "Good On" Time When Switching from RYTARY®

AMRX· Amneal Pharmaceuticals Inc.
Health Care
Original source

Companies

  • AMRX
    Amneal Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Apr 17UpdateUBS$19.00
  • Dec 9UpdateBarclays$15.00
  • Jun 6UpdateGoldman$12.00
  • Feb 24UpdateAnalyst$12.00
  • Sep 6UpdateJP Morgan$9.00

Related

  • SEC10h
    SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.
  • SEC1d
    SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.
  • SEC1d
    SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.
  • SEC1d
    SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.
  • SEC1d
    SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.
  • SEC1d
    SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.
  • SEC1d
    SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.
  • SEC1d
    Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Regulation FD Disclosure
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022